SCHEMBL7018923

SCHEMBL7018923

Cc1cc(Cl)nc(N[C@@H](C)c2ccccc2)n1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 3/20 0.51
KCNN3 Q9UGI6 1/20 0.49
LMNA P02545 2/20 0.46
HTR7 P34969 4/20 0.44
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
NUDT1 P36639 1/20 0.42
TTK P33981 1/20 0.41
HDAC3 O15379 3/20 0.40
HDAC1 Q13547 3/20 0.40
HDAC2 Q92769 3/20 0.40
HDAC6 Q9UBN7 3/20 0.40
ALDH1A1 P00352 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ADRA1D P25100 1/20 0.40
ADRA1A P35348 1/20 0.40
ADRA1B P35368 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7016449 0.90 IDH1 (0.55) IDH1KCNN3HTR7NUDT1HDAC3
SCHEMBL12410906 0.81 GAA (0.52) LMNAKMT2AMEN1ALDH1A1L3MBTL1
SCHEMBL7594415 0.81 IDH1 (0.48) IDH1LMNAHTR7KMT2AMEN1
SCHEMBL7021773 0.81 IDH1 (0.48) IDH1LMNAHTR7KMT2AMEN1
SCHEMBL4388171 0.78 GAA (0.53) IDH1KCNN3HTR7HDAC3HDAC1
SCHEMBL10480049 0.78 GAA (0.53) IDH1KCNN3HTR7HDAC3HDAC1
SCHEMBL1369837 0.77 GRK6 (0.46) IDH1KCNN3ALDH1A1
SCHEMBL1369836 0.77 GRK6 (0.46) IDH1KCNN3ALDH1A1
SCHEMBL7014490 0.76 HTR7 (0.59) IDH1HTR7ADRA1DADRA1AADRA1B
SCHEMBL9698795 0.75 HTR7 (0.62) IDH1LMNAHTR7KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1206265-B1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2003-11-12 EP disclosed
US-6498165-B1 PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS MERCK & CO., INC. 2002-12-24 US disclosed
EP-1206265-A4 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2002-08-07 EP disclosed
EP-1206265-A1 SRC KINASE INHIBITOR COMPOUNDS Merck & Co., Inc. (US) 2002-05-22 EP disclosed
WO-2001000213-A1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO., INC. (US) 2001-01-04 WO disclosed